Resources - RESEARCH LITERACY
Stopping semaglutide, tirzepatide or other GLP-1 medicines: what the trials show happens to weight and appetite
What happens when you stop Ozempic, Wegovy or Mounjaro: the follow-up trials that measured weight regain, how fast appetite returns, what happened to blood pressure and blood sugar, why the medicines are licensed as ongoing treatment, and the questions to take to a prescriber before stopping.
When people stop semaglutide or tirzepatide, most of the weight comes back. That is not an opinion or a warning; it is what the follow-up trials measured. In the semaglutide trial extension, participants regained about two-thirds of their lost weight within a year of stopping, and the improvements in blood pressure and blood sugar largely reversed with it. In the tirzepatide withdrawal trial, those switched to placebo regained about 14% of body weight in a year while those who continued kept losing. This article sets out what those trials found, how fast appetite returns and why, what happened to the other health measures, why the medicines are licensed as ongoing treatments, what the evidence does not cover, and the questions that belong with a prescriber before anyone stops. It is not advice to start, stop or continue anything.
Why the question matters more for this class than most
Most weight-loss interventions are compared on how much weight comes off. For the GLP-1 medicines, the more important number turned out to be how much comes back, because the trials that followed people after stopping found the answer was most of it. That finding shapes everything else about the drugs: how they are licensed, how NICE has framed NHS access, and what a realistic conversation with a prescriber sounds like. It also explains why "a course of Ozempic" is a misunderstanding of what the medicine does. The drug changes appetite and stomach emptying while it is present. When it is gone, so is the change.
Semaglutide: the STEP 1 extension
STEP 1 was the 68-week trial that established semaglutide's weight-management licence, with average weight loss of about 14.9% at 2.4 mg weekly. A subset of participants was then followed for a further year off treatment, with no drug and no continued lifestyle programme. Published in 2022, the extension found that those who had been on semaglutide regained about two-thirds of the weight they had lost, an average of around 11.6 percentage points back from a 17.3% loss in that subgroup, so that by 120 weeks they were about 5.6% below their starting weight. The improvements seen during treatment in blood pressure, cholesterol and blood-sugar markers moved back towards baseline alongside the weight.
A companion trial, STEP 4, approached the question the other way: everyone took semaglutide for 20 weeks, then half were switched to placebo without knowing it. Over the next 48 weeks the continuing group lost a further 7.9% while the placebo group regained 6.9%, a gap of about 15 percentage points. The two trials agree: the effect depends on the drug being present.
Tirzepatide: SURMOUNT-4
SURMOUNT-4 used the same design as STEP 4. Adults with obesity took tirzepatide for 36 weeks, losing on average about 20.9% of body weight, and were then randomised to continue or to switch to placebo for a further 52 weeks. Those who continued lost a further 5.5%. Those on placebo regained about 14%, ending roughly 10% below where they started, with the gap between the groups about 25 percentage points at the end. Blood pressure, lipids and blood-sugar markers followed the weight in each group. The result, published in 2024, matched the semaglutide findings and is the reason tirzepatide's licence and NICE guidance treat it as continuing treatment.
Why appetite returns, and how quickly
Both drugs are engineered to last: semaglutide has a half-life of about a week and tirzepatide about five days, which is what allows once-weekly dosing. After the last dose the level in the blood falls by half each half-life, so within four to five weeks the drug is essentially gone. As it clears, the effects fade: stomach emptying speeds back up, the sense of fullness after meals shortens, and the reduced interest in food that many people describe returns. No withdrawal syndrome has been described in the trials or the product information; what the trials measured was the underlying appetite, which the drug was suppressing, returning to what it was. People who have adjusted their eating over a year of treatment often describe the return of hunger as abrupt, because they had stopped noticing its absence. Knowing the timetable in advance, roughly a month from the last dose to the drug being gone, lets that change be anticipated rather than experienced as a surprise.
What the trials did not measure
The follow-up periods were a year or a little more. Whether regain continues to baseline, stops short, or overshoots beyond two years is not well described. The trials stopped the drugs abruptly; none tested a gradual reduction, so there is no evidence on whether tapering changes the outcome, and the licences do not describe one. The trials removed lifestyle support at the same time as the drug in some designs, so the pure effect of stopping the medicine while keeping the diet and activity changes is not cleanly separated. And the participants were trial volunteers with monitoring; how regain plays out in ordinary use, with less support, is being studied now through real-world data. The honest summary is that the direction is certain, the size is approximately known for the first year, and the details are still being filled in.
Body composition and what comes back
Weight lost on these medicines is a mixture of fat and lean tissue, as with any substantial weight loss, and weight regained is not automatically the same mixture. Studies of weight cycling in general suggest that regained weight tends to be proportionally more fat than the weight lost, especially without resistance training, though the GLP-1-specific data on this are thin. It is one reason the conversation about stopping includes what happens to muscle, and why NICE and the product information recommend diet and activity alongside treatment.
How the licences and NICE reflect this
Because the effect depends on continuing, semaglutide and tirzepatide are licensed for weight management as ongoing treatment alongside a reduced-calorie diet and increased activity, with no defined course length. NICE's guidance for the NHS adds a practical limit: semaglutide for weight management is funded for a maximum of two years within specialist services under NICE TA875, and tirzepatide access is phased by clinical priority. Those limits are about NHS resources and the state of long-term evidence, not a statement that the drugs stop working at two years, and they are one reason the question of what happens afterwards is asked so often. A prescriber managing someone through the end of an NHS course, or through a decision to stop for any reason, is working from exactly the trial data above.
Why regain is not a personal failure
The regain data are often read as a judgement on the people in the trials, as if they had stopped trying. The physiology says otherwise. Weight loss by any method lowers the hormones that signal fullness and raises the ones that signal hunger, and those changes persist for a long time after the weight is gone; the body defends its previous weight with a persistence that willpower rarely matches. GLP-1 medicines work by overriding part of that signal. Remove the override and the signal returns, in people who had made exactly the same effort as those who kept taking the drug. This is the same reason weight regained after any diet is so common, and it is why the trial designers expected what they found. Understanding it changes the conversation from "why did I fail" to "what does maintenance actually require", which is a question with practical answers.
What the wider maintenance literature describes
The trials that followed people off treatment did not test maintenance strategies directly. The wider weight-management guidance, including NICE's, describes the same components: regular self-monitoring of weight, continued structured physical activity, a diet that supports lean mass, sustained contact with a clinician or programme, and, where a prescriber has agreed one, a plan for what happens if weight returns. None of these is specific to GLP-1 medicines, and none replaces the drug's effect on appetite, but they are the components NICE expects to accompany a prescription in the first place.
The questions that belong with a prescriber
- Why is stopping being considered: cost, side effects, reaching a goal, supply, or the end of a funded period? Each has a different set of options.
- What is the maintenance plan: diet, activity, follow-up weighing, and who is providing support once the drug is gone?
- Does anything need monitoring as the drug clears, particularly blood sugar in people with diabetes, blood pressure, and any other medicine whose dose was adjusted during weight loss?
- Is a lower maintenance dose, a different medicine, or a pause rather than a stop an option in this case?
- What is the plan if weight returns: a threshold for restarting, and whether restarting is possible under the same funding or prescription?
These are decisions with real trade-offs, made for one person, by someone who can see their history and can be there afterwards. That is what a prescriber is for, and it is why this article describes the evidence and stops.
This article is educational content only and is not medical advice or a recommendation to start, stop or change any medicine. Semaglutide and tirzepatide are prescription-only medicines; decisions about them belong with a prescriber. Trial figures are reported as trial figures. Vivera Education sells nothing.
Frequently asked
- What happens when you stop taking semaglutide?
- In the STEP 1 extension, people who stopped semaglutide after 68 weeks regained on average about two-thirds of the weight they had lost within a year of stopping, and the improvements in blood pressure, blood lipids and blood sugar largely reversed. Appetite returns as the drug clears, over a few weeks.
- What happens when you stop tirzepatide?
- In SURMOUNT-4, people who lost weight on tirzepatide for 36 weeks and were then switched to placebo regained about 14% of body weight over the following year, while those who continued lost a further 5.5%. The difference between the two groups at the end was about 25 percentage points.
- Do you regain all the weight after stopping GLP-1 medicines?
- Not all, on average, within the first year: the trials show much of the lost weight returning, roughly half in the tirzepatide withdrawal trial and about two-thirds in the semaglutide one, with wide individual variation. Longer follow-up is limited. The lifestyle changes made during treatment influence how much returns.
- How quickly does appetite come back after stopping?
- Semaglutide has a half-life of about a week and tirzepatide about five days, so both are largely cleared within four to five weeks of the last dose, and appetite and stomach emptying return to their previous pattern over that period. People commonly report increased hunger within a few weeks.
- Are GLP-1 medicines meant to be taken for life?
- They are licensed as ongoing treatments alongside diet and activity, not as courses, because the trials show the effect depends on continuing. Whether and how long to continue is an individual decision made with a prescriber. NHS weight-management access for semaglutide is limited to two years under NICE TA875 (checked September 2026).
- Can you taper off semaglutide or tirzepatide?
- The trials stopped the drugs abruptly and did not test tapering, so there is no evidence either way on whether stepping down slows regain. The licences do not specify a tapering schedule. This is a question for the prescriber, not for a forum.
- Does stopping GLP-1 medicines cause withdrawal symptoms?
- No withdrawal syndrome has been described in the trials or the product information. What returns is the underlying appetite and, in people with diabetes, higher blood sugar. Some people describe low mood around regain; the trials did not study this and the cause is not established.
- What should I ask before stopping?
- Why stopping is being considered; what the plan is for maintaining weight, including diet, activity and follow-up; whether blood sugar, blood pressure or other conditions need monitoring as the drug clears; and whether a different dose or medicine is an option. These are prescriber questions.
The studies and sources behind this page
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.